Nicotine salts, co-crystals, and salt co-crystal complexes

Patent metadata

Field	Value
Publication number	US-12180179-B2
Application number	US-202117545785-A
Country	US
Kind code	B2
Filing date	Dec 8, 2021
Priority date	May 27, 2014
Publication date	Dec 31, 2024
Grant date	Dec 31, 2024

Abstract

The invention provides certain nicotine salt co-crystals and provides novel polymorphic forms of certain nicotine salts. In particular, certain nicotine salt-co-crystals are described, including nicotine and two different coformers. The invention further provides methods of preparation and characterization of nicotine salts, co-crystals, and salt co-crystals. In addition, tobacco products, including smoking articles, smokeless tobacco products, and electronic smoking articles comprising nicotine salts, co-crystals, and/or salt co-crystals are also provided.

First claim

What is claimed:

1. An oral product comprising one or more salt co-crystals selected from the group consisting of:
a salt-co-crystal of nicotine, L-malic acid, and succinic acid;
a salt-co-crystal of nicotine, orotic acid, and succinic acid; and
a salt-co-crystal of nicotine, fumaric acid, and nicotinamide.

2. The oral product of claim 1 , selected from the group consisting of loose moist snuff (e.g., snus); loose dry snuff; chewing tobacco; pelletized tobacco pieces; extruded or formed tobacco strips, pieces, rods, cylinders or sticks; finely divided ground powders; finely divided or milled agglomerates of powdered pieces and components; flake-like pieces; molded tobacco pieces; gums; rolls of tape-like films; readily water-dissolvable or water-dispersible films or strips; meltable compositions; lozenges; tablets, microtabs; pastilles; and capsule-like materials possessing an outer shell and an inner region.

3. The oral product of claim 1 , in the form of a pouched product comprising a water-permeable outer pouch containing a smokeless tobacco composition.

4. The oral product of claim 3 , wherein the smokeless tobacco composition comprises the one or more salt co-crystals.

5. The oral product of claim 3 , wherein an interior or exterior pouch lining of the water-permeable outer pouch comprises the one or more salt co-crystals.

6. The oral product of claim 1 , further comprising one or more excipients selected from the group consisting of fillers, carriers, thickeners, film formers and binders, antiadherents, glidants, humectants, preservatives, antioxidants, surfactants, dyes, pigments, lubricants, processing aids, and combinations thereof.

7. The oral product of claim 1 , further comprising one or more salts, sweeteners, pH adjusters, buffering agents, effervescing materials, oral care additives, syrups, and combinations thereof.

8. The oral product of claim 1 , further comprising one or more lipid components.

9. The oral product of claim 1 , further comprising one or more encapsulated additives.

10. A pharmaceutical product comprising one or more salt co-crystals selected from the group consisting of:
a salt-co-crystal of nicotine, L-malic acid, and succinic acid;
a salt-co-crystal of nicotine, orotic acid, and succinic acid; and
a salt-co-crystal of nicotine, fumaric acid, and nicotinamide.

11. The pharmaceutical product of claim 10 , wherein the product is an oral product in a form selected from the group consisting of a pill, tablet, lozenge, capsule, caplet, pouch, and gum.

12. The pharmaceutical product of claim 10 , wherein the product is a cream or liquid.

13. The pharmaceutical product of claim 12 , wherein the cream is in the form of a salve, ointment, or paste.

14. The pharmaceutical product of claim 12 , wherein the liquid is in the form of a spray or enema.

15. The pharmaceutical product of claim 10 , wherein the one or more salt co-crystals is incorporated within an inhaler device for delivery.

16. The pharmaceutical product of claim 15 , wherein the inhaler is a metered dose inhaler, dry powder inhaler, or nebulizer.

17. The pharmaceutical product of claim 10 , further comprising one or more pharmaceutically acceptable components selected from the group consisting of salts, sweeteners, fillers, flavorants, antiadherents, glidants, preservatives, antioxidants, surfactants, dyes, pigments, lubricants, processing aids, and combinations thereof.

18. A lozenge comprising one or more salt co-crystals selected from the group consisting of:
a salt-co-crystal of nicotine, L-malic acid, and succinic acid;
a salt-co-crystal of nicotine, orotic acid, and succinic acid; and
a salt-co-crystal of nicotine, fumaric acid, and nicotinamide; and
at least about 50% by weight isomalt.

19. The lozenge of claim 18 , comprising at least about 80% by weight isomalt.

20. The lozenge of claim 18 , further comprising maltitol syrup.

21. The lozenge of claim 18 , further comprising one or more salts, sweeteners, flavorings, or combinations thereof.

Assignees

• Reynolds Tobacco Co R

Inventors

• Dull Gary M
• Del Rio Gancedo Susana
• Julia Judit Galcera

Classifications

• C07D239/557

  with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid · CPC title

• C07C59/245

  containing hydroxy or O-metal groups · CPC title

• C07C59/40

  Unsaturated compounds · CPC title

• C07D213/82

  in position 3 · CPC title

• C07C59/235

  Saturated compounds containing more than one carboxyl group · CPC title